Cullinan Therapeutics, Inc. (NASDAQ:CGEM) experienced a 1.6% increase in its share price on Tuesday following an announcement that the U.S. Food and Drug Administration provided favorable feedback after an End-of-Phase 1 meeting for CLN-049. CLN-049 is a bispecific T cell engager targeting FLT3 and CD3, currently under evaluation in patients with acute myeloid leukemia (AML).
The FDA discussion concentrated on the proposed Phase 2 development pathway for CLN-049. As a result of those conversations, Cullinan intends to launch a potentially registrational Phase 2 study in patients with relapsed or refractory AML in the third quarter of 2026. The study blueprint agreed with the agency includes a brief dose-optimization segment followed by seamless transition into a single-arm cohort at the recommended Phase 2 dose.
Mechanistically, CLN-049 is designed to bind FLT3-expressing leukemia cells and to engage T cells via CD3. The molecule binds both mutated and non-mutated forms of FLT3, enabling targeting regardless of FLT3 mutational status. Cullinan presented data at the 2025 American Society of Hematology Annual Meeting showing that CLN-049 demonstrated clinical activity and a tolerable safety profile in patients with relapsed or refractory AML.
Looking ahead, the company said it will provide an update from the dose-escalation portion of the study in the fourth quarter of 2026. In parallel, Cullinan will start a Phase 1/2 study to assess CLN-049 in combination with venetoclax and azacitidine in patients with previously untreated AML.
CLN-049 has been granted Orphan Drug designation and Fast Track designation from the FDA for the treatment of relapsed or refractory AML. The company noted that roughly 23,000 people in the United States are diagnosed with AML each year, and that five-year survival in relapsed or refractory disease is 10% or less.
Key points
- FDA provided positive feedback after an End-of-Phase 1 meeting, prompting a planned Phase 2 start in Q3 2026 - impacts biotech and healthcare sectors.
- The Phase 2 design includes a short dose-optimization phase with seamless progression to a single-arm cohort at the recommended Phase 2 dose - relevant to clinical trial operations and regulatory strategy.
- Cullinan is advancing combination testing of CLN-049 with venetoclax and azacitidine and will report dose-escalation updates in Q4 2026 - affecting oncology drug development pipelines and hospital oncology services.
Risks and uncertainties
- The Phase 2 study is described as "potentially registrational," indicating regulatory outcomes remain to be determined - this affects biotech investors and regulatory affairs planning.
- Additional data from the dose-escalation portion will not be available until the fourth quarter of 2026, leaving near-term clinical-readout uncertainty - this impacts market expectations for the stock and capital planning.
- While prior data showed clinical activity and a safety profile, ongoing trial results and combination-study outcomes are pending and will determine future development steps - this affects clinical development timelines and oncology service providers.